The states of California and Massachusetts prohibit manufacturers from offering co-pay assistance for prescription drugs like Esbriet that have a generic equivalent. Effective May 2022, patients residing in these states are no longer eligible for the Esbriet Co-pay Program.
If your patients have financial concerns related to Esbriet, Genentech Access Solutions offers referrals to independent co-pay assistance foundations for eligible patients who are publicly or commercially insured. To learn more, call (844) 372-7438.
The information contained in this section of the site is intended for US specialty pharmacy representatives only. Click "OK" if you are a specialty pharmacy representative.
Eligible commercially insured patients who are prescribed Esbriet for an FDA-approved use can receive up to $25,000 in assistance per 12-month period.
Have a temporary reference number and want to return to the confirmation screen?
Enter your information here:
Esbriet is a prescription medicine used to treat people with a lung disease called idiopathic pulmonary fibrosis (IPF).
It is not known if Esbriet is safe and effective in children.
Before you take Esbriet, tell your doctor if you:
Esbriet may cause serious side effects, including:
Your doctor may change your dose or discontinue Esbriet if side effects do not go away.
The most common side effects of Esbriet include upper respiratory tract infections, feeling tired, headache, dizziness, loss of appetite, sinusitis, insomnia, or weight loss.
These are not all the possible side effects of Esbriet.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch or to Genentech at 1-888-835-2555.
Please see full Prescribing Information, including Patient Information, for additional important safety information.